Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bisoprolol + ramipril
- Development stage
- Phase 4
- Lead developer
- Neopharmed Gentili
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bisoprolol + ramipril is a fixed-dose combination (FDC) therapy that combines a beta-blocker (bisoprolol) with an angiotensin-converting enzyme (ACE) inhibitor (ramipril). This combination targets different blood pressure control systems with complementary mechanisms of action. The FDC format is designed to reduce tablet burden, improve treatment adherence, and enhance blood pressure control in patients with hypertension. Clinical studies have demonstrated bioequivalence for the 10/5 mg strength and the absence of clinically relevant pharmacokinetic drug-drug interactions between bisoprolol and ramipril[1][5].
- Brand names
- RamiBiso APONTIS
- Other names
- ramipril/bisoprololbisoprolol/ramipril
02
Targets
ACE (Angiotensin Converting Enzyme)ADRB1 (β1)
Beyond the preview
Go deeper on bisoprolol + ramipril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bisoprolol + ramipril.